Arena Analyst Call Adds Little To Lorcaserin Dialog
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech adds little clarity to the situation surrounding the rejection of its obesity drug lorcaserin by FDA in a conference call with stakeholders.